Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
- PMID: 28930295
- DOI: 10.1038/nrgastro.2017.109
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Abstract
NAFLD is one of the most important causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming decades, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NAFLD vary worldwide, usually parallel to the prevalence of obesity, but a substantial proportion of patients are lean. The large number of patients with NAFLD with potential for progressive liver disease creates challenges for screening, as the diagnosis of NASH necessitates invasive liver biopsy. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their need for management. While awaiting the development effective therapies, this disease warrants the attention of primary care physicians, specialists and health policy makers.
Similar articles
-
Non-alcoholic fatty liver disease - A global public health perspective.J Hepatol. 2019 Mar;70(3):531-544. doi: 10.1016/j.jhep.2018.10.033. Epub 2018 Nov 9. J Hepatol. 2019. PMID: 30414863 Review.
-
Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: What we need in the future.Liver Int. 2018 Feb;38 Suppl 1:47-51. doi: 10.1111/liv.13643. Liver Int. 2018. PMID: 29427488 Review.
-
Progress and challenges in the prevention and control of nonalcoholic fatty liver disease.Med Res Rev. 2019 Jan;39(1):328-348. doi: 10.1002/med.21515. Epub 2018 May 30. Med Res Rev. 2019. PMID: 29846945 Review.
-
Prevalence of biopsy-proven non-alcoholic fatty liver disease in severely obese subjects without metabolic syndrome.Clin Obes. 2016 Apr;6(2):117-23. doi: 10.1111/cob.12132. Epub 2016 Feb 8. Clin Obes. 2016. PMID: 26856683
-
Epidemiology and natural history of non-alcoholic fatty liver disease.Metabolism. 2016 Aug;65(8):1017-25. doi: 10.1016/j.metabol.2016.01.012. Epub 2016 Jan 29. Metabolism. 2016. PMID: 26997539 Review.
Cited by
-
Dietary Rhythms and MASLD-Related Hepatocellular Carcinoma.Cancers (Basel). 2024 Oct 14;16(20):3481. doi: 10.3390/cancers16203481. Cancers (Basel). 2024. PMID: 39456575 Free PMC article. Review.
-
Infections at the nexus of metabolic-associated fatty liver disease.Arch Toxicol. 2021 Jul;95(7):2235-2253. doi: 10.1007/s00204-021-03069-1. Epub 2021 May 24. Arch Toxicol. 2021. PMID: 34027561 Free PMC article. Review.
-
Nonalcoholic fatty liver disease and cardiovascular disease phenotypes.SAGE Open Med. 2020 Jun 20;8:2050312120933804. doi: 10.1177/2050312120933804. eCollection 2020. SAGE Open Med. 2020. PMID: 32612827 Free PMC article. Review.
-
Interleukin-18 in metabolism: From mice physiology to human diseases.Front Endocrinol (Lausanne). 2022 Oct 12;13:971745. doi: 10.3389/fendo.2022.971745. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36313762 Free PMC article. Review.
-
Hypoglycemic agents for non-alcoholic fatty liver disease with type 2 diabetes mellitus: A protocol for systematic review and network meta-analysis.Medicine (Baltimore). 2020 Aug 7;99(32):e21568. doi: 10.1097/MD.0000000000021568. Medicine (Baltimore). 2020. PMID: 32769900 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical